Attenuation of Clostridium difficile toxin-induced damage to epithelial barrier by ecto-5′-nucleotidase (CD73) and adenosine receptor signaling

Neurogastroenterology and Motility

Volumn 25, Issue 6, 2013, Pages

  Patrick Schenck, L ^a   Hirota, S A ^a   Hirota, C L ^b   Boasquevisque, P ^a   Tulk, S E ^a   Li, Y ^a   Wadhwani, A ^b   Doktorchik, C T A ^a   Macnaughton, W K ^b   Beck, P L ^a   Macdonald, J A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

AdoRA; Cdf infection associated disease; Epithelial permeability; Hypoxia inducible factor 1; Infectious colitis

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE PHOSPHATE; ADENOSINE RECEPTOR; ALPHA,BETA METHYLENEADENOSINE DIPHOSPHATE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; ECTO 5' NUCLEOTIDASE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; PROTEIN ZO1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL INFILTRATION; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; CELL TRANSPORT; CONTROLLED STUDY; ELECTRIC RESISTANCE; FEMALE; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TIGHT JUNCTION; TRANSEPITHELIAL ELECTRICAL RESISTANCE;

5'-NUCLEOTIDASE; BACTERIAL PROTEINS; BACTERIAL TOXINS; CELL LINE, TUMOR; ENTEROTOXINS; EPITHELIAL CELLS; HUMANS; INTESTINAL MUCOSA; PERMEABILITY; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION; TIGHT JUNCTIONS;

EID: 84878018464     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12139     Document Type: Article

References (41)

1. Jarvis WR, Schlosser J, Jarvis AA, Chinn RY. National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control 2009; 37: 263-70.
2. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 2010; 4: 409-16.
3. Lo Vecchio A, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012; 28: 1-9.
4. Jafari NV, Allan E, Bajaj-Elliott M. Human intestinal epithelial responses to Clostridium difficile. Methods Mol Biol 2010; 646: 135-46.
5. Pothoulakis C. Effects of Clostridium difficile toxins on epithelial cell barrier. Ann N Y Acad Sci 2000; 915: 347-56.
6. Carter GP, Rood JI, Lyras D. The role of toxin A and toxin B in the virulence of Clostridium difficile. Trends Microbiol 2012; 20: 21-9.
7. Davies AH, Roberts AK, Shone CC, Acharya KR. Super toxins from a super bug: structure and function of Clostridium difficile toxins. Biochem J 2011; 436: 517-26.
8. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005; 18: 247-63.
9. Mitchell MJ, Laughon BE, Lin S. Biochemical studies on the effect of Clostridium difficile toxin B on actin in vivo and in vitro. Infect Immun 1987; 55: 1610-5.
10. Hecht G, Koutsouris A, Pothoulakis C, LaMont JT, Madara JL. Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology 1992; 102: 416-23.
11. Chen ML, Pothoulakis C, LaMont JT. Protein kinase C signaling regulates ZO-1 translocation and increased paracellular flux of T84 colonocytes exposed to Clostridium difficile toxin A. J Biol Chem 2002; 277: 4247-54.
12. Hecht G, Pothoulakis C, LaMont JT, Madara JL. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest 1988; 82: 1516-24.
13. Nusrat A, von Eichel-Streiber C, Turner JR, Verkade P, Madara JL, Parkos CA. Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect Immun 2001; 69: 1329-36.
14. Zemljic M, Rupnik M, Scarpa M, Anderluh G, Palu G, Castagliuolo I. Repetitive domain of Clostridium difficile toxin B exhibits cytotoxic effects on human intestinal epithelial cells and decreases epithelial barrier function. Anaerobe 2010; 16: 527-32.
15. Johal SS, Solomon K, Dodson S, Borriello SP, Mahida YR. Differential effects of varying concentrations of Clostridium difficile toxin A on epithelial barrier function and expression of cytokines. J Infect Dis 2004; 189: 2110-9.
16. Feltis BA, Wiesner SM, Kim AS et al. Clostridium difficile toxins A and B can alter epithelial permeability and promote bacterial paracellular migration through HT-29 enterocytes. Shock 2000; 14: 629-34.
17. Hirota SA, Fines K, Ng J et al. Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury. Gastroenterology 2010; 139(259-269): e253.
18. Louis NA, Robinson AM, MacManus CF, Karhausen J, Scully M, Colgan SP. Control of IFN-alphaA by CD73: implications for mucosal inflammation. J Immunol 2008; 180: 4246-55.
19. Synnestvedt K, Furuta GT, Comerford KM et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 2002; 110: 993-1002.
20. Lennon PF, Taylor CT, Stahl GL, Colgan SP. Neutrophil-derived 5′-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med 1998; 188: 1433-43.
21. Eltzschig HK, Ibla JC, Furuta GT et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 2003; 198: 783-96.
22. Hart ML, Grenz A, Gorzolla IC, Schittenhelm J, Dalton JH, Eltzschig HK. Hypoxia-inducible factor-1alpha-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5′-nucleotidase (CD73) and the A2B adenosine receptor. J Immunol 2011; 186: 4367-74.
23. Frick JS, MacManus CF, Scully M, Glover LE, Eltzschig HK, Colgan SP. Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. J Immunol 2009; 182: 4957-64.
24. Warren CA, Calabrese GM, Li Y et al. Effects of adenosine A2A receptor activation and alanyl-glutamine in Clostridium difficile toxin-induced ileitis in rabbits and cecitis in mice. BMC Infect Dis 2012; 12: 13.
25. de Araujo Junqueira AF, Dias AA, Vale ML et al. Adenosine deaminase inhibition prevents Clostridium difficile toxin A-induced enteritis in mice. Infect Immun 2011; 79: 653-62.
26. Hirota SA, Iablokov V, Tulk SE et al. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure. Infect Immun 2012; 80: 4474-84.
27. Swystun VA, Renaux B, Moreau F et al. Serine proteases decrease intestinal epithelial ion permeability by activation of protein kinase Czeta. Am J Physiol Gastrointest Liver Physiol 2009; 297: G60-70.
28. Zehendner CM, Librizzi L, de Curtis M, Kuhlmann CR, Luhmann HJ. Caspase-3 contributes to ZO-1 and Cl-5 tight-junction disruption in rapid anoxic neurovascular unit damage. PLoS ONE 2011; 6: e16760.
29. Parkos CA, Colgan SP, Delp C, Arnaout MA, Madara JL. Neutrophil migration across a cultured epithelial monolayer elicits a biphasic resistance response representing sequential effects on transcellular and paracellular pathways. J Cell Biol 1992; 117: 757-64.
30. Madara JL, Patapoff TW, Gillece-Castro B et al. 5′-adenosine monophosphate is the neutrophil-derived paracrine factor that elicits chloride secretion from T84 intestinal epithelial cell monolayers. J Clin Invest 1993; 91: 2320-5.
31. Burger RM, Lowenstein JM. 5′-Nucleotidase from smooth muscle of small intestine and from brain. Inhibition of nucleotides. Biochemistry 1975; 14: 2362-6.
32. Antonioli L, Fornai M, Colucci R et al. Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications. Pharmacol Ther 2008; 120: 233-53.
33. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5′-nucleotidase (CD73). Purinergic Signal 2006; 2: 351-60.
34. Pothoulakis C, Triadafilopoulos G, Clark M, Franzblau C, LaMont JT. Clostridium difficile cytotoxin inhibits protein synthesis in fibroblasts and intestinal mucosa. Gastroenterology 1986; 91: 1147-53.
35. Sotnikov I, Louis NA. CD73-dependent regulation of interferon alphaA and interleukin-10 in the inflamed mucosa. Sci World J 2010; 10: 2167-80.
36. Hirota SA, Beck PL, MacDonald JA. Targeting hypoxia-inducible factor-1 (HIF-1) signaling in therapeutics: implications for the treatment of inflammatory bowel disease. Recent Pat Inflamm Allergy Drug Discov 2009; 3: 1-16.
37. Hasko G, Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 2008; 83: 447-55.
38. Li Y, Figler RA, Kolling G et al. Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment. BMC Infect Dis 2012; 12: 342.
39. Warren CA, Li Y, Calabrese GM et al. Contribution of adenosine A(2B) receptors in Clostridium difficile intoxication and infection. Infect Immun 2012; 80: 4463-73.
40. Szabo N, Kincses ZT, Vecsei L. Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists. Expert Opin Drug Metab Toxicol 2011; 7: 441-55.
41. Wang L, Fan J, Thompson LF et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 2011; 121: 2371-82.